{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:50:34Z","timestamp":1789415434917,"version":"build-2803163510"},"reference-count":191,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Liver transplantation for cancer indications has gained momentum in recent years. This review is intended to optimize the care setting of liver transplant candidates by highlighting current indications, technical aspects and barriers with available solutions to facilitate the guidance of available strategies for healthcare professionals in specialized centres.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A review of the most recent relevant literature was conducted for all the cancer indications of liver transplantation including colorectal cancer liver metastases, hilar cholangiocarcinoma, intrahepatic cholangiocarcinoma, neuroendocrine tumours, hepatocellular carcinoma and hepatic epitheloid haemangioendothelioma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Transplant benefit from the best available evidence, including SECA I, SECA II, TRANSMET studies for colorectal liver metastases, various preoperative protocols for cholangiocarcinoma patients, standard, extended selection criteria for hepatocellular carcinoma and neuroendocrine tumours, are discussed. Innovative approaches to deal with organ shortages, including machine-perfused deceased grafts, living donor liver transplantation and RAPID procedures, are also explored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Cancer indications for liver transplantation are here to stay, and the selection criteria among all cancer groups are likely to evolve further with improved prognostication of tumour biology using adjuncts such as radiomics, cancer genomics, and circulating DNA and RNA status. International prospective registry-based studies could overcome the limitations of smaller patient cohorts and lack of level 1 evidence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjsopen\/zraf034","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T07:17:16Z","timestamp":1747466236000},"source":"Crossref","is-referenced-by-count":8,"title":["Liver transplantation as a treatment for cancer: comprehensive review"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2375-1141","authenticated-orcid":false,"given":"Bobby V M","family":"Dasari","sequence":"first","affiliation":[{"name":"Department of Liver Transplantation and HBP Surgery, Queen Elizabeth Hospital, Birmingham ,","place":["UK"]},{"name":"Department of Immunology and Immunotherapy, University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-9336","authenticated-orcid":false,"given":"Pal-Dag","family":"Line","sequence":"additional","affiliation":[{"name":"Department of Transplantation Medicine, Oslo University Hospital, Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9527-8723","authenticated-orcid":false,"given":"Gonzalo","family":"Sapisochin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Multi-Organ Transplant Program, University Health Network , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6867-228X","authenticated-orcid":false,"given":"Taizo","family":"Hibi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences , Kumamoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4839-5852","authenticated-orcid":false,"given":"Prashant","family":"Bhangui","sequence":"additional","affiliation":[{"name":"Liver Transplantation and Hepatobiliary Surgery, Medanta Institute of Liver Transplantation and Regenerative Medicine, Medanta-The Medicity , Gurgaon (Delhi NCR) ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim J","family":"Halazun","sequence":"additional","affiliation":[{"name":"Department of Liver Transplantation and Hepatobiliary Surgery, NYU Grossman School of Medicine, NYU Langone Health, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishir","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Immunology and Immunotherapy, University of Birmingham , Birmingham ,","place":["UK"]},{"name":"Department of Hepatology, Queen Elizabeth Hospital , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Queen Elizabeth Hospital , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T J","family":"Magyar","sequence":"additional","affiliation":[{"name":"Department of Abdominal Transplant & HBP Surgical Oncology, Toronto General Hospital, University Health Network, University of Toronto, Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Donnelly","sequence":"additional","affiliation":[{"name":"Department of Liver Transplantation and Hepatobiliary Surgery, NYU Grossman School of Medicine, NYU Langone Health, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"BRC Clinical Fellow Liver Medicine, University Hospitals of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"2025052712050367700_zraf034-B1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/SLA.0000000000004071","article-title":"Transplant oncology in primary and metastatic liver tumors: principles, evidence, and opportunities","volume":"273","author":"Sapisochin","year":"2021","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B2","doi-asserted-by":"crossref","first-page":"100965","DOI":"10.1016\/j.jhepr.2023.100965","article-title":"Transplant oncology\u2014current indications and strategies to advance the field","volume":"6","author":"Krendl","year":"2023","journal-title":"JHEP Rep"},{"key":"2025052712050367700_zraf034-B3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.surg.2018.10.024","article-title":"What is transplant oncology?","volume":"165","author":"Hibi","year":"2019","journal-title":"Surgery"},{"key":"2025052712050367700_zraf034-B4","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","article-title":"Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference","volume":"104","author":"Mehta","year":"2020","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/TP.0000000000003175","article-title":"The ILTS consensus conference on transplant oncology: setting the stage","volume":"104","author":"Sapisochin","year":"2020","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.hbpd.2023.10.007","article-title":"Ex vivo liver resection and auto-transplantation as an alternative for the treatment of liver malignancies: progress and challenges","volume":"23","author":"Yang","year":"2024","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2025052712050367700_zraf034-B7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/SLA.0000000000006024","article-title":"Liver histology predicts liver regeneration and outcome in ALPPS","volume":"279","author":"Lopez-Lopez","year":"2024","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B8","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1007\/s00464-022-09270-2","article-title":"The rex shunt for left portal vein reconstruction during hepatectomy for malignancy using of rex-shunt in adults for oncoliver surgery","volume":"36","author":"Conticchio","year":"2022","journal-title":"Surg Endosc"},{"key":"2025052712050367700_zraf034-B9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/jhbp.870","article-title":"Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition","volume":"28","author":"Nagino","year":"2021","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025052712050367700_zraf034-B10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/SLA.0000000000005121","article-title":"Liver venous deprivation or associating liver partition and portal vein ligation for staged hepatectomy?","volume":"274","author":"Chebaro","year":"2021","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B11","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.hpb.2023.05.365","article-title":"Liver surgery in the 2020s: ante-situm and in-situ resection are still indicated\u2014a single-center study","volume":"25","author":"Fard-Aghaie","year":"2023","journal-title":"HPB"},{"key":"2025052712050367700_zraf034-B12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00000658-200012000-00006","article-title":"Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors","volume":"232","author":"Adam","year":"2000","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/SLA.0000000000002511","article-title":"ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a scandinavian multicenter randomized controlled trial (LIGRO trial)","volume":"267","author":"Sandstrom","year":"2018","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B14","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.SLA.0000065265.16728.C0","article-title":"Preoperative portal vein embolization for extended hepatectomy","volume":"237","author":"Hemming","year":"2003","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2016.10.028","article-title":"Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: a pooled analysis of clinical studies by gruppo oncologico del nord ovest","volume":"73","author":"Cremolini","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025052712050367700_zraf034-B16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","article-title":"Liver transplantation for nonresectable liver metastases from colorectal cancer","volume":"257","author":"Hagness","year":"2013","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/SLA.0000000000005703","article-title":"Transplantation for nonresectable colorectal liver metastases\u2014long term follow-up of the first prospective pilot study","volume":"278","author":"Solheim","year":"2023","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/SLA.0000000000003404","article-title":"Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases","volume":"271","author":"Dueland","year":"2020","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B19","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2020.08.015","article-title":"Liver transplantation for secondary liver tumours: the difficult balance between survival and recurrence","volume":"73","author":"Line","year":"2020","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s11605-015-3026-6","article-title":"The worse prognosis of right-sided compared with left-sided colon cancers: a systematic review and meta-analysis","volume":"20","author":"Yahagi","year":"2016","journal-title":"J Gastrointest Surg"},{"key":"2025052712050367700_zraf034-B21","doi-asserted-by":"crossref","first-page":"e0217411","DOI":"10.1371\/journal.pone.0217411","article-title":"Primary tumour location affects survival after resection of colorectal liver metastases: a two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score","volume":"14","author":"Gasser","year":"2019","journal-title":"PLoS One"},{"key":"2025052712050367700_zraf034-B22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/bjs5.50278","article-title":"Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study)","volume":"4","author":"Smedman","year":"2020","journal-title":"BJS Open"},{"key":"2025052712050367700_zraf034-B23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2468-1253(21)00219-3","article-title":"Liver transplantation for non-resectable colorectal liver metastases: the international hepato-pancreato-biliary association consensus guidelines","volume":"6","author":"Bonney","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025052712050367700_zraf034-B24","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.3390\/cancers14205042","article-title":"PET-uptake in liver metastases as method to predict tumor biological behavior in patients transplanted for colorectal liver metastases developing lung recurrence","volume":"14","author":"Dueland","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025052712050367700_zraf034-B25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/cancers16010019","article-title":"Metabolic tumor volume from 18F-FDG PET\/CT in combination with radiologic measurements to predict long-term survival following transplantation for colorectal liver metastases","volume":"16","author":"Grut","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025052712050367700_zraf034-B26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s12149-022-01796-8","article-title":"Metabolic tumor volume predicts long-term survival after transplantation for unresectable colorectal liver metastases: 15 years of experience from the SECA study","volume":"36","author":"Grut","year":"2022","journal-title":"Ann Nucl Med"},{"key":"2025052712050367700_zraf034-B27","first-page":"283","article-title":"The prognostic value of (18)F-FDG PET\/CT prior to liver transplantation for nonresectable colorectal liver metastases","volume":"4","author":"Grut","year":"2017","journal-title":"Eur J Nucl Med Mol I"},{"key":"2025052712050367700_zraf034-B28","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","article-title":"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial","volume":"404","author":"Adam","year":"2024","journal-title":"Lancet"},{"key":"2025052712050367700_zraf034-B29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/XCS.0000000000000734","article-title":"Toronto management of initially unresectable liver metastases from colorectal cancer in a living donor liver transplant program","volume":"237","author":"Rajendran","year":"2023","journal-title":"J Am Coll Surgeons"},{"key":"2025052712050367700_zraf034-B30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamasurg.2022.0300","article-title":"Recipient and donor outcomes after living-donor liver transplant for unresectable colorectal liver metastases","volume":"157","author":"Hernandez-Alejandro","year":"2022","journal-title":"JAMA Surg"},{"key":"2025052712050367700_zraf034-B31","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/SLA.0000000000001165","article-title":"A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept","volume":"262","author":"Line","year":"2015","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/SLA.0000000000005726","article-title":"Auxilliary liver transplantation according to the RAPID procedure in non-cirrhotic patients\u2014technical aspects and early outcomes","volume":"277","author":"Settmacher","year":"2023","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/SLA.0000000000002861","article-title":"Paradigm shift in the management of irresectable colorectal liver metastases","volume":"270","author":"K\u00f6nigsrainer","year":"2019","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12957-018-1549-5","article-title":"Living donor liver transplantation with two-stage hepatectomy for patients with isolated, irresectable colorectal liver\u2014the LIVER-T(W)O-HEAL study","volume":"17","author":"Rauchfu\u00df","year":"2019","journal-title":"World J Surg Oncol"},{"key":"2025052712050367700_zraf034-B35","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1002\/lt.22356","article-title":"Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations","volume":"17","author":"Pomfret","year":"2011","journal-title":"Liver Transplant"},{"key":"2025052712050367700_zraf034-B36","doi-asserted-by":"crossref","DOI":"10.1007\/s13304-024-01919-y","article-title":"Advocating for a \u201cshift-to-left\u201d in transplant oncology: left grafts, RAPID and dual graft","author":"Cillo","year":"2024","journal-title":"Updat Surg"},{"key":"2025052712050367700_zraf034-B37","first-page":"659","article-title":"Homotransplantation of the liver in humans","volume":"117","author":"Starzl","year":"1963","journal-title":"Surg Gynecol Obstet"},{"key":"2025052712050367700_zraf034-B38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00000658-198510000-00001","article-title":"Role of liver transplantation in cancer therapy","volume":"202","author":"Iwatsuki","year":"1985","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B39","first-page":"734","article-title":"Hepatic transplantation for primary and metastatic cancers of the liver","volume":"110","author":"Penn","year":"1991","journal-title":"Surg"},{"key":"2025052712050367700_zraf034-B40","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0002-9610(05)80696-8","article-title":"Is liver transplantation indicated for cholangiocarcinoma?","volume":"166","author":"Goldstein","year":"1993","journal-title":"Am J Surg"},{"key":"2025052712050367700_zraf034-B41","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1097\/00007890-200004270-00019","article-title":"Liver transplantation for cholangiocarcinoma: results in 207 patients","volume":"69","author":"Meyer","year":"2000","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/lv.2000.6143","article-title":"Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoradiation for cholangiocarcinoma","volume":"6","author":"De Vreede","year":"2000","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B43","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1002\/lt.20266","article-title":"Transplantation for hilar cholangiocarcinoma","volume":"10","author":"Heimbach","year":"2004","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B44","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0016-5107(02)70442-2","article-title":"Tissue sampling at ERCP in suspected malignant biliary strictures (part 1)","volume":"56","author":"De Bellis","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"2025052712050367700_zraf034-B45","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1053\/j.gastro.2006.08.021","article-title":"Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures","volume":"131","author":"Moreno Luna","year":"2006","journal-title":"Gastroenterology"},{"key":"2025052712050367700_zraf034-B46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4254\/wjh.v12.i10.693","article-title":"Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma","volume":"12","author":"Akateh","year":"2020","journal-title":"World J Hepatol"},{"key":"2025052712050367700_zraf034-B47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.suc.2023.09.004","article-title":"Liver transplantation for hilar cholangiocarcinoma","volume":"104","author":"Sonnenday","year":"2024","journal-title":"Surg Clin North Am"},{"key":"2025052712050367700_zraf034-B48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","article-title":"Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma","volume":"242","author":"Rea","year":"2005","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B49","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/COC.0000000000001002","article-title":"Neoadjuvant therapy regimens for hilar cholangiocarcinoma before liver transplant","volume":"46","author":"Keltner","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"2025052712050367700_zraf034-B50","doi-asserted-by":"crossref","first-page":"908687","DOI":"10.3389\/fonc.2022.908687","article-title":"Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver transplantation: an institution experience","volume":"12","author":"Abdelrahim","year":"2022","journal-title":"Front Oncol"},{"key":"2025052712050367700_zraf034-B51","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2025052712050367700_zraf034-B52","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3390\/curroncol29020050","article-title":"Systemic treatment for metastatic biliary tract cancer: state of the art and a glimpse to the future","volume":"29","author":"Rizzo","year":"2022","journal-title":"Curr Oncol"},{"key":"2025052712050367700_zraf034-B53","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2025052712050367700_zraf034-B54","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2025052712050367700_zraf034-B55","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s11605-020-04721-4","article-title":"Liver transplantation for peri-hilar cholangiocarcinoma","volume":"24","author":"Tan","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"2025052712050367700_zraf034-B56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40472-021-00313-6","article-title":"New breakthroughs for liver transplantation of cholangiocarcinoma","volume":"8","author":"McMillan","year":"2021","journal-title":"Curr Transplant Rep"},{"key":"2025052712050367700_zraf034-B57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"key":"2025052712050367700_zraf034-B58","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/lt.21107","article-title":"Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma","volume":"13","author":"Mantel","year":"2007","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B59","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/SLA.0000000000005641","article-title":"Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study","volume":"276","author":"Breuer","year":"2022","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B60","doi-asserted-by":"crossref","first-page":"910871","DOI":"10.3389\/fonc.2022.910871","article-title":"Feasibility and efficacy of adjuvant chemotherapy with gemcitabine after liver transplantation for perihilar cholangiocarcinoma\u2014a multi-center, randomized, controlled trial (pro-duct001)","volume":"12","author":"Schmelzle","year":"2022","journal-title":"Front Oncol"},{"key":"2025052712050367700_zraf034-B61","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/01.tp.0000253551.43583.d1","article-title":"Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"82","author":"Heimbach","year":"2006","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","article-title":"Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"273","author":"Cambridge","year":"2021","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B63","doi-asserted-by":"crossref","first-page":"100516","DOI":"10.1016\/j.trre.2019.100516","article-title":"Liver transplantation for hilar cholangiocarcinoma: a systematic review","volume":"34","author":"Machairas","year":"2020","journal-title":"Transplant Rev"},{"key":"2025052712050367700_zraf034-B64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/lt.23757","article-title":"Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma","volume":"20","author":"Welling","year":"2014","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B65","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jamcollsurg.2015.01.064","article-title":"Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma?","volume":"221","author":"Croome","year":"2015","journal-title":"J Am Coll Surg"},{"key":"2025052712050367700_zraf034-B66","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B67","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B68","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"2025052712050367700_zraf034-B69","first-page":"1","article-title":"Incidence trend and competing risk analysis of patients with intrahepatic cholangiocarcinoma: a population-based study","volume":"9","author":"Xing","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025052712050367700_zraf034-B70","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/TP.0000000000003212","article-title":"Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS transplant oncology consensus conference","volume":"104","author":"Sapisochin","year":"2020","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B71","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.28744","article-title":"Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"2025052712050367700_zraf034-B72","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.32258","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time?","volume":"75","author":"Sapisochin","year":"2022","journal-title":"Hepatology"},{"key":"2025052712050367700_zraf034-B73","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOT.0000000000001136","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma: who, when and how","volume":"29","author":"Achurra","year":"2024","journal-title":"Curr Opin Organ Transplant"},{"key":"2025052712050367700_zraf034-B74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"Alvaro","year":"2023","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B75","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"2025052712050367700_zraf034-B76","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1097\/TP.0000000000003539","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates","volume":"105","author":"Ziogas","year":"2021","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B77","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025052712050367700_zraf034-B78","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/ajt.16906","article-title":"Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"McMillan","year":"2022","journal-title":"Am J Transplant"},{"key":"2025052712050367700_zraf034-B79","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/lt.25807","article-title":"Comparison of wait-list mortality between cholangiocarcinoma and hepatocellular carcinoma liver transplant candidates","volume":"26","author":"Ziogas","year":"2020","journal-title":"Liver Transplant"},{"key":"2025052712050367700_zraf034-B80","author":"University Health Network"},{"key":"2025052712050367700_zraf034-B81","doi-asserted-by":"crossref","first-page":"102649","DOI":"10.1016\/j.ctrv.2023.102649","article-title":"Molecular profiling in cholangiocarcinoma: a practical guide to next-generation sequencing","volume":"122","author":"Stenzinger","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2025052712050367700_zraf034-B82","doi-asserted-by":"crossref","first-page":"101951","DOI":"10.1016\/j.mcp.2024.101951","article-title":"Intrahepatic cholangiocarcinoma biomarkers: towards early detection and personalized pharmacological treatments","volume":"73","author":"Capuozzo","year":"2024","journal-title":"Mol Cell Probes"},{"key":"2025052712050367700_zraf034-B83","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1245\/s10434-022-11463-x","article-title":"Systematic review and meta-analysis of prognostic factors for early recurrence in intrahepatic cholangiocarcinoma after curative-intent resection","volume":"29","author":"Choi","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2025052712050367700_zraf034-B84","doi-asserted-by":"crossref","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study","volume":"23","author":"White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M et al.","year":"2022","journal-title":"Lancet Reg Health Eur."},{"key":"2025052712050367700_zraf034-B85","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025052712050367700_zraf034-B86","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.surg.2017.05.006","article-title":"Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review","volume":"162","author":"Moris","year":"2017","journal-title":"Surgery"},{"key":"2025052712050367700_zraf034-B87","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jso.23973","article-title":"Liver transplantation for metastatic neuroendocrine tumors: outcomes and prognostic variables","volume":"112","author":"Sher","year":"2015","journal-title":"J Surg Oncol"},{"key":"2025052712050367700_zraf034-B88","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/TP.0b013e3182081312","article-title":"Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis","volume":"91","author":"M\u00e1th\u00e9","year":"2011","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B89","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/SLA.0b013e31828ee17c","article-title":"Liver transplantation for neuroendocrine tumors in Europe\u2014results and trends in patient selection: a 213-case European liver transplant registry study","volume":"257","author":"Le Treut","year":"2013","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B90","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1111\/ajt.13831","article-title":"The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors","volume":"16","author":"Mazzaferro","year":"2016","journal-title":"Am J Transplant"},{"key":"2025052712050367700_zraf034-B91","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2007.07.004","article-title":"Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?","volume":"47","author":"Mazzaferro","year":"2007","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B92","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1097\/TP.0000000000003802","article-title":"Postrecurrence survival after liver transplantation for liver metastases from neuroendocrine tumors","volume":"105","author":"Sposito","year":"2021","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B93","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2025052712050367700_zraf034-B94","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"Ioannou","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025052712050367700_zraf034-B95","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"2025052712050367700_zraf034-B96","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0030-1247133","article-title":"Current strategy for staging and treatment: the BCLC update and future prospects","volume":"30","author":"Forner","year":"2010","journal-title":"Semin Liver Dis"},{"key":"2025052712050367700_zraf034-B97","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Forner","year":"2012","journal-title":"Lancet"},{"key":"2025052712050367700_zraf034-B98","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"31","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"2025052712050367700_zraf034-B99","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"2025052712050367700_zraf034-B101","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"2025052712050367700_zraf034-B102","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/hep.24680","article-title":"Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis","volume":"55","author":"Fuks","year":"2012","journal-title":"Hepatology"},{"key":"2025052712050367700_zraf034-B103","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/SLA.0000000000001442","article-title":"Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes?","volume":"264","author":"Bhangui","year":"2016","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B104","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/SLA.0b013e318273bad0","article-title":"Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy?","volume":"256","author":"Adam","year":"2012","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B105","doi-asserted-by":"crossref","first-page":"101269","DOI":"10.1016\/j.jceh.2023.08.005","article-title":"2023 update of Indian national association for study of the liver consensus on management of intermediate and advanced hepatocellular carcinoma: the puri III recommendations","volume":"14","author":"Kumar","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"2025052712050367700_zraf034-B106","doi-asserted-by":"crossref","first-page":"102406","DOI":"10.1016\/j.jceh.2024.102406","article-title":"Evolving global etiology of hepatocellular carcinoma (HCC): insights and trends for 2024","volume":"15","author":"Koshy","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"2025052712050367700_zraf034-B107","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/jlts.2001.25458","article-title":"Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma","volume":"7","author":"Herrero","year":"2001","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B108","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00000658-200204000-00012","article-title":"Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters","volume":"235","author":"Roayaie","year":"2002","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B109","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/lt.20237","article-title":"Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma","volume":"10","author":"Kneteman","year":"2004","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B110","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/lt.21095","article-title":"Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the international registry of hepatic tumors in liver transplantation","volume":"13","author":"Onaca","year":"2007","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B111","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"2025052712050367700_zraf034-B112","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"2025052712050367700_zraf034-B113","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"2025052712050367700_zraf034-B114","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/SLA.0000000000002964","article-title":"Is it time to abandon the Milan criteria?: results of a bicoastal US collaboration to redefine hepatocellular carcinoma liver transplantation selection policies","volume":"268","author":"Halazun","year":"2018","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000106910","article-title":"Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series","volume":"25","author":"Sugawara","year":"2007","journal-title":"Dig Dis"},{"key":"2025052712050367700_zraf034-B116","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000106908","article-title":"Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria","volume":"25","author":"Takada","year":"2007","journal-title":"Dig Dis"},{"key":"2025052712050367700_zraf034-B117","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/lt.21445","article-title":"Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center","volume":"14","author":"Lee","year":"2008","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B118","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/TP.0b013e3181943bee","article-title":"Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation","volume":"87","author":"Taketomi","year":"2009","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B119","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"2025052712050367700_zraf034-B120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/tri.13391","article-title":"Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule\u2014a retrospective study","volume":"32","author":"Shimamura","year":"2019","journal-title":"Transpl Int"},{"key":"2025052712050367700_zraf034-B121","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/lt.25956","article-title":"Incorporating tumor biology to predict hepatocellular carcinoma recurrence in patients undergoing living donor liver transplantation using expanded selection criteria","volume":"27","author":"Bhangui","year":"2021","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B122","doi-asserted-by":"crossref","first-page":"82","DOI":"10.21037\/tgh.2017.09.12","article-title":"Hepatocellualr cancer and liver transplantation: from the Tower of Babel towards a uniform language","volume":"2","author":"Lerut","year":"2017","journal-title":"Transl Gastroenterol Hepatol"},{"key":"2025052712050367700_zraf034-B123","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2020.03.018","article-title":"Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant","volume":"73","author":"Cucchetti","year":"2020","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B124","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.3748\/wjg.v19.i48.9183","article-title":"Transplant benefit for patients with hepatocellular carcinoma","volume":"19","author":"Vitale","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2025052712050367700_zraf034-B125","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B126","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"2025052712050367700_zraf034-B127","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"key":"2025052712050367700_zraf034-B128","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.3748\/wjg.v12.i47.7561","article-title":"Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus","volume":"12","author":"Minagawa","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025052712050367700_zraf034-B129","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/MCG.0b013e3182a8a254","article-title":"Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact","volume":"48","author":"Lee","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"2025052712050367700_zraf034-B130","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B131","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"2025052712050367700_zraf034-B132","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B133","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2025052712050367700_zraf034-B134","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/lt.24610","article-title":"Macrovascular invasion is not an absolute contraindication for living donor liver transplantation","volume":"23","author":"Lee","year":"2017","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B135","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/lt.24782","article-title":"The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation","volume":"23","author":"Choi","year":"2017","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B136","doi-asserted-by":"crossref","first-page":"8867","DOI":"10.18632\/oncotarget.12817","article-title":"Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition","volume":"8","author":"Cheng","year":"2017","journal-title":"Oncotarget"},{"key":"2025052712050367700_zraf034-B137","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1097\/TP.0000000000003162","article-title":"Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging","volume":"104","author":"Soin","year":"2020","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B138","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/lt.26257","article-title":"Deceased donor liver transplantation after radioembolization for hepatocellular carcinoma and portal vein tumoral thrombosis: a pilot study","volume":"27","author":"Serenari","year":"2021","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B139","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.22225","article-title":"Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy","volume":"107","author":"Mehrabi","year":"2006","journal-title":"Cancer"},{"key":"2025052712050367700_zraf034-B140","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/SLA.0b013e31815c2a70","article-title":"The place of liver transplantation in the treatment of hepatic epithelioid hemangioendothelioma: report of the European liver transplant registry","volume":"246","author":"Lerut","year":"2007","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B141","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11605-007-0247-3","article-title":"Long-term outcomes following liver transplantation for hepatic hemangioendothelioma: the UNOS experience from 1987 to 2005","volume":"12","author":"Rodriguez","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"2025052712050367700_zraf034-B142","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00000478-200105000-00019","article-title":"Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma","volume":"25","author":"Mendlick","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"2025052712050367700_zraf034-B143","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/gcc.20886","article-title":"A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites","volume":"50","author":"Errani","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"2025052712050367700_zraf034-B144","article-title":"Guidance to liver transplant programs and the national liver review board for adult MELD exception review","author":"U.S. Department of Health & Human Services: Organ Procurement and Transplantation Network","year":"2017"},{"key":"2025052712050367700_zraf034-B145","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/TP.0000000000002982","article-title":"Liver transplantation for hepatic epithelioid hemangioendothelioma is facilitated by exception points with acceptable long-term outcomes","volume":"104","author":"Brahmbhatt","year":"2020","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B146","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.hpb.2022.03.013","article-title":"Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States","volume":"24","author":"Kaltenmeier","year":"2022","journal-title":"HPB (Oxford)"},{"key":"2025052712050367700_zraf034-B147","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/hepr.13364","article-title":"Liver transplantation in Japan: registry by the Japanese liver transplantation society","volume":"49","author":"Umeshita","year":"2019","journal-title":"Hepatol Res"},{"key":"2025052712050367700_zraf034-B148","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4285\/kjt.20.0049","article-title":"Prognosis of hepatic epithelioid hemangioendothelioma after living donor liver transplantation","volume":"35","author":"Na","year":"2021","journal-title":"Korean J Transplant"},{"key":"2025052712050367700_zraf034-B149","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ccr3.2558","article-title":"Hepatic epithelioid hemangioendothelioma successfully treated with living donor liver transplantation: a case report and literature review","volume":"8","author":"Fukuhara","year":"2019","journal-title":"Clin Case Rep"},{"key":"2025052712050367700_zraf034-B150","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/TP.0000000000001603","article-title":"Hepatic epithelioid hemangioendothelioma and adult liver transplantation: proposal for a prognostic score based on the analysis of the ELTR-ELITA registry","volume":"101","author":"Lai","year":"2017","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B151","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.esmoop.2021.100170","article-title":"Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","volume":"6","author":"Stacchiotti","year":"2021","journal-title":"ESMO Open"},{"key":"2025052712050367700_zraf034-B152","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s13304-024-01907-2","article-title":"Extra-hepatic epithelioid hemangioendothelioma: pushing the limit with sirolimus in combination with liver transplantation","volume":"76","author":"di Francesco","year":"2024","journal-title":"Updates Surg"},{"key":"2025052712050367700_zraf034-B153","doi-asserted-by":"crossref","first-page":"791272","DOI":"10.3389\/fphar.2022.791272","article-title":"Transforming growth factor-beta (TGF-\u03b2) signaling in cancer\u2013a betrayal within","volume":"13","author":"Baba","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025052712050367700_zraf034-B154","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JHC.S224471","article-title":"Angiogenesis in hepatocellular carcinoma; pathophysiology, targeted therapy, and role of imaging","volume":"7","author":"Moawad","year":"2020","journal-title":"J Hepatocell Carcinoma"},{"key":"2025052712050367700_zraf034-B155","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B156","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1097\/00007890-200212270-00017","article-title":"Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection of lower immunosuppression?","volume":"74","author":"Vivarelli","year":"2002","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B157","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/TP.0b013e3181c3c540","article-title":"Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma","volume":"89","author":"Vivarelli","year":"2010","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B158","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1097\/TP.0000000000004487","article-title":"Induction immunosuppression does not worsen tumor recurrence after liver transplantation for hepatocellular carcinoma","volume":"107","author":"Durkin","year":"2023","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B159","doi-asserted-by":"crossref","first-page":"20236","DOI":"10.1038\/s41598-023-46803-8","article-title":"Cumulative exposure to tacrolimus during early period after liver transplantation does not affect the recurrence of hepatocellular carcinoma","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"2025052712050367700_zraf034-B160","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int"},{"key":"2025052712050367700_zraf034-B161","doi-asserted-by":"crossref","first-page":"80","DOI":"10.21037\/tgh.2017.09.06","article-title":"Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?","volume":"2","author":"Lerut","year":"2017","journal-title":"Transl Gastroenterol Hepatol"},{"key":"2025052712050367700_zraf034-B162","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.23437","article-title":"Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma","volume":"51","author":"Toso","year":"2010","journal-title":"Hepatology"},{"key":"2025052712050367700_zraf034-B163","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/lt.21953","article-title":"Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation","volume":"15","author":"Chinnakotla","year":"2009","journal-title":"Liver Transplantation"},{"key":"2025052712050367700_zraf034-B164","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.transproceed.2008.03.165","article-title":"Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria","volume":"40","author":"Zhou","year":"2008","journal-title":"Transplant Proc"},{"key":"2025052712050367700_zraf034-B165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.hbpd.2020.06.002","article-title":"Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: preliminary experience","volume":"19","author":"Yang","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2025052712050367700_zraf034-B166","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/lt.21420","article-title":"Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"14","author":"Zimmerman","year":"2008","journal-title":"Liver Transplantation"},{"key":"2025052712050367700_zraf034-B167","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1016\/j.transproceed.2014.08.045","article-title":"Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series","volume":"46","author":"Ferreiro","year":"2014","journal-title":"Transplant Proc"},{"key":"2025052712050367700_zraf034-B168","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B169","doi-asserted-by":"crossref","first-page":"e14211","DOI":"10.1111\/ctr.14211","article-title":"Evolving utilization of donation after circulatory death livers in liver transplantation: the day of DCD has come","volume":"35","author":"Haque","year":"2021","journal-title":"Clin Transplant"},{"key":"2025052712050367700_zraf034-B170","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1600-6143.2011.03894.x","article-title":"Donation after cardiac death liver transplant recipients have an increased frequency of acute kidney injury","volume":"12","author":"Leithead","year":"2012","journal-title":"Am J Transplant"},{"key":"2025052712050367700_zraf034-B171","doi-asserted-by":"crossref","first-page":"e944077","DOI":"10.12659\/AOT.944077","article-title":"Comparative study of acute kidney injury in liver transplantation: donation after circulatory death versus brain death","volume":"29","author":"Hilger","year":"2024","journal-title":"Ann Transplant"},{"key":"2025052712050367700_zraf034-B172","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/TP.0000000000003819","article-title":"Donor warm ischemia time in DCD liver transplantation-working group report from the ILTS DCD, liver preservation, and machine perfusion consensus conference","volume":"105","author":"Kalisvaart","year":"2021","journal-title":"Transplantation"},{"key":"2025052712050367700_zraf034-B173","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2018.10.005","article-title":"Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation","volume":"70","author":"Schlegel","year":"2019","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B174","doi-asserted-by":"crossref","first-page":"11697","DOI":"10.3389\/ti.2023.11697","article-title":"Beyond the concepts of elder and marginal in DCD liver transplantation: a prospective observational matched-cohort study in the Italian clinical setting","volume":"36","author":"Fallani","year":"2023","journal-title":"Transpl Int"},{"key":"2025052712050367700_zraf034-B175","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13139","article-title":"Systematic review and meta-analysis of liver transplantation using grafts from deceased donors aged over 70 years","volume":"31","author":"Dasari","year":"2017","journal-title":"Clin Transplant"},{"key":"2025052712050367700_zraf034-B176","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/ajt.13699","article-title":"Liver transplantation using grafts from donors after circulatory death: a propensity score-matched study from a single center","volume":"16","author":"Laing","year":"2016","journal-title":"Am J Transplant"},{"key":"2025052712050367700_zraf034-B177","doi-asserted-by":"crossref","first-page":"1458996","DOI":"10.3389\/frtra.2024.1458996","article-title":"Impact of donor transaminases on liver transplant utilisation and unnecessary organ discard: national registry cohort study","volume":"3","author":"Dobbins","year":"2024","journal-title":"Front Transplant"},{"key":"2025052712050367700_zraf034-B178","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/biomedicines9020161","article-title":"Viability assessment in liver transplantation\u2014what is the impact of dynamic organ preservation?","volume":"9","author":"Panconesi","year":"2021","journal-title":"Biomedicines"},{"key":"2025052712050367700_zraf034-B179","doi-asserted-by":"crossref","first-page":"e017733","DOI":"10.1136\/bmjopen-2017-017733","article-title":"Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial","volume":"7","author":"Laing","year":"2017","journal-title":"BMJ Open"},{"key":"2025052712050367700_zraf034-B180","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41467-020-16251-3","article-title":"Transplantation of discarded livers following viability testing with normothermic machine perfusion","volume":"11","author":"Mergental","year":"2020","journal-title":"Nat Commun"},{"key":"2025052712050367700_zraf034-B181","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.hpb.2019.01.004","article-title":"Can hypothermic oxygenated perfusion (HOPE) rescue futile DCD liver grafts?","volume":"21","author":"Muller","year":"2019","journal-title":"HPB (Oxford)"},{"key":"2025052712050367700_zraf034-B182","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2024.08.030","article-title":"Assessment of liver graft quality during hypothermic oxygenated perfusion: the first international validation study","volume":"82","author":"Eden","year":"2024","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B183","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jhep.2022.12.030","article-title":"A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation","volume":"78","author":"Schlegel","year":"2023","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B184","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa2031532","article-title":"Hypothermic machine perfusion in liver transplantation\u2014a randomized trial","volume":"384","author":"van Rijn","year":"2021","journal-title":"N Engl J Med"},{"key":"2025052712050367700_zraf034-B185","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/ajt.17022","article-title":"Sequential hypothermic and normothermic machine perfusion enables safe transplantation of high-risk donor livers","volume":"22","author":"van Leeuwen","year":"2022","journal-title":"Am J Transplant"},{"key":"2025052712050367700_zraf034-B186","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jhep.2018.12.013","article-title":"Normothermic regional perfusion vs. super-rapid recovery in controlled donation after circulatory death liver transplantation","volume":"70","author":"Hessheimer","year":"2019","journal-title":"J Hepatol"},{"key":"2025052712050367700_zraf034-B187","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/SLA.0000000000004258","article-title":"Hypothermic oxygenated liver perfusion (HOPE) prevents tumor recurrence in liver transplantation from donation after circulatory death","volume":"272","author":"Mueller","year":"2020","journal-title":"Ann Surg"},{"key":"2025052712050367700_zraf034-B188","doi-asserted-by":"crossref","first-page":"102411","DOI":"10.1016\/j.eclinm.2023.102411","article-title":"Prolonged hypothermic machine perfusion enables daytime liver transplantation\u2014an IDEAL stage 2 prospective clinical trial","volume":"68","author":"Br\u00fcggenwirth","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025052712050367700_zraf034-B189","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/lt.26251","article-title":"Verifying the benefits of radical treatment in posttransplant hepatocellular carcinoma oligo-recurrence: a propensity score analysis","volume":"28","author":"Au","year":"2022","journal-title":"Liver Transpl"},{"key":"2025052712050367700_zraf034-B190","first-page":"71","article-title":"Post liver transplant recurrence in patients with hepatocellular carcinoma: not necessarily the end of the road!","volume":"6","author":"Bhangui","year":"2020","journal-title":"Hepatoma Res"},{"key":"2025052712050367700_zraf034-B191","doi-asserted-by":"crossref","first-page":"95849","DOI":"10.5500\/wjt.v14.i3.95849","article-title":"SIMAP500: a novel risk score to identify recipients at higher risk of hepatocellular carcinoma recurrence following liver transplantation","volume":"14","author":"Alnagar","year":"2024","journal-title":"World J Transplant"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/9\/3\/zraf034\/63215011\/zraf034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/9\/3\/zraf034\/63215011\/zraf034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:05:39Z","timestamp":1748361939000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zraf034\/8134035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":191,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zraf034","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,7]]},"article-number":"zraf034"}}